Nanoform Finland Plc (NANOFH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanoform Finland Plc (NANOFH) has a cash flow conversion efficiency ratio of -0.076x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.38 Million ≈ $-3.95 Million USD) by net assets (€44.58 Million ≈ $52.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Nanoform Finland Plc to measure how much of total assets are equity-financed.
Nanoform Finland Plc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Nanoform Finland Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Nanoform Finland Plc (NANOFH) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Nanoform Finland Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanoform Finland Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rein Therapeutics Inc
NASDAQ:RNTX
|
-0.295x |
|
Mediaco Holding Inc
NASDAQ:MDIA
|
0.001x |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
-0.191x |
|
Asetek A/S
F:A31
|
0.018x |
|
GrabAGun Digital Holdings Inc.
NYSE:PEW
|
N/A |
|
Axon Partners Group S.A.
MC:APG
|
0.065x |
|
Asia Pacific Satellite Inc
KQ:211270
|
0.011x |
|
Cheer Time Enterprise Co Ltd
TW:3229
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Nanoform Finland Plc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Nanoform Finland Plc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Nanoform Finland Plc (NANOFH) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €60.03 Million ≈ $70.18 Million |
€-18.28 Million ≈ $-21.37 Million |
-0.304x | -13.22% |
| 2023-12-31 | €66.95 Million ≈ $78.27 Million |
€-18.00 Million ≈ $-21.05 Million |
-0.269x | -16.79% |
| 2022-12-31 | €87.21 Million ≈ $101.96 Million |
€-20.08 Million ≈ $-23.48 Million |
-0.230x | -35.58% |
| 2021-12-31 | €84.49 Million ≈ $98.78 Million |
€-14.35 Million ≈ $-16.78 Million |
-0.170x | +24.86% |
| 2020-12-31 | €62.64 Million ≈ $73.23 Million |
€-14.16 Million ≈ $-16.55 Million |
-0.226x | +69.08% |
| 2019-12-31 | €7.93 Million ≈ $9.27 Million |
€-5.80 Million ≈ $-6.78 Million |
-0.731x | -144.64% |
| 2018-12-31 | €5.03 Million ≈ $5.88 Million |
€-1.50 Million ≈ $-1.76 Million |
-0.299x | -111.03% |
| 2017-12-31 | €-246.96K ≈ $-288.72K |
€-669.18K ≈ $-782.34K |
2.710x | -- |
About Nanoform Finland Plc
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) na… Read more